· Investment Strategies · 3 sources · Updated · Verified
Tandem Health’s $100M Series B: EQT Scaleup’s First Healthcare Bet
Tandem Health closed a $100M Series B led by EQT’s Scaleup Europe Fund on September 14, 2026 — the fund’s first healthcare check — at 10,000 care organisations across 14 markets and $160M total funding. Valuation was not disclosed.
By Venture Capital Tracker Editorial
Tandem Health closed a $100 million Series B on September 14, 2026, led by the Scaleup Europe Fund managed by EQT — the fund’s first healthcare investment — with Kinnevik, Northzone, Amino Collective, and Visionaries returning. The raise follows a $50 million Series A in 2025 and brings total funding to $160 million. Valuation was not disclosed (company, Sky News via The1News).
Europe’s public–private scale-up vehicle just wrote its first health AI cheque into a company that already claims pan-European distribution and MDR Class IIa certifications — not a U.S. ambient-scribe transplant.
Key facts
- Company
- Tandem Health (tandemhealth.ai) — AI Medical Assistant for European clinics
- Round
- $100M Series B; $160M lifetime
- Lead
- Scaleup Europe Fund (EQT) — first healthcare deal for the fund
- Participants
- Kinnevik, Northzone, Amino Collective, Visionaries
- Traction (company)
- 10,000 care organisations; 14 markets; 130+ EHR integrations
- Named logos
- Ramsay Santé, Humanitas; NHS access via Accurx (Sky News)
- Efficacy claim
- Peer-reviewed: 29% less admin time; 30% better job satisfaction; 30% less admin stress
- Valuation / ARR
- Not disclosed
EQT / Scaleup Europe Fund, Kinnevik, Northzone, Amino Collective, and Visionaries are not in our /fund/ directory — editorial names only.
Who uses the product — and for what job
Users: European clinicians and care organisations that need documentation, coding, and decision support that survive EU MDR, sovereignty, and local EHR fragmentation — not a U.S. Epic-first ambient scribe bolt-on.
Job today: AI Scribe + Coding Assistant + Clinical Decision Support across the visit, each independently certified as Class IIa under EU MDR (company). Job next: expand into an AI-native clinic operating system — triage, scheduling, patient communications — while deepening 130+ regional EHR integrations.
Distribution signal: Sky News reports an Accurx partnership that put Tandem in front of hundreds of thousands of NHS practitioners. Treat that as a channel claim, not a paid-seat count; the diligence spine is organisation count, certifications, and named large providers.
Why now
- WHO cites a European health-and-social-care workforce shortfall rising toward 4 million by 2030; Eurostat’s dependency ratios make admin-hour recovery a budget line, not a nice-to-have.
- Scaleup Europe Fund already marked European AI sovereignty with Mistral and space/deeptech names like Iceye — healthcare was the missing vertical for a fund targeting ~€5B.
- Tandem’s release frames the product as built in Europe for Europe (ISO 27001 / 13485 / 42001, German C5, Spanish ENS High, French HDS) against US tools retrofitted for GDPR and MDR.
Why Scaleup Europe Fund / EQT — portfolio fit
EQT’s Scaleup vehicle is designed for European companies that can become continental platforms, not single-country SaaS. Tandem’s pitch matches that mandate: 14 markets, clinician-led delivery teams, and regulatory-grade devices that LPs can defend as infrastructure rather than chatbot experiments.
Nils Petter Nygaard (EQT / Scaleup Europe Fund) called Tandem one of the few healthtechs that has already shown pan-European scale at 10,000+ organisations — language that echoes the fund’s Mistral thesis: pick category leaders that can absorb public + private capital without waiting for a Silicon Valley series letter.
Compare: The Exploration Company and Mistral also carried Scaleup Europe Fund ink in September — different sectors, same European scale-up book.
Competitive map
| Approach | Tradeoff |
|---|---|
| U.S. ambient scribes (Ambience, Abridge, etc.) | Strong Epic depth; weaker EU MDR / multi-EHR path |
| Legacy EHR copilots | Incumbent distribution; slow AI product cycles |
| Generic LLM wrappers | Fast demos; fail compliance and coding accuracy |
| Tandem EU-native stack | Regulatory + multi-market fit; must keep proving ROI beyond scribe |
What is not proven
- Valuation, dilution, and board seats beyond the fundraising announcement.
- Revenue / ARR, retention, and paid vs channelled NHS seats.
- Independent verification of the 29% / 30% / 30% peer-reviewed admin metrics.
- Timeline and product proof for the “clinic operating system” expansion.
Practical takeaway
- Founders (health AI EU): Sell certifications + local EHR depth + named providers before U.S. comps; Scaleup Europe Fund is now actively writing health checks.
- Investors: Diligence organisation quality vs vanity count, Accurx economics, and whether Class IIa devices create a real switching moat.
- Operators / clinicians: Relevant if you already run European outpatient or multi-site care and need MDR-grade documentation + coding in one stack.
Follow Venture Capital Tracker on Google
Add VCT as a preferred source to see more of our venture-capital reporting in Google Search.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.
